Carregant...
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recen...
Guardat en:
| Publicat a: | Genome Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5080691/ https://ncbi.nlm.nih.gov/pubmed/27782862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-016-0365-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|